IPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation

dc.contributor.authorTristá Noguero, Alba
dc.contributor.authorFernández Carasa, Irene
dc.contributor.authorCalatayud, Carles
dc.contributor.authorBermejo Casadesús, Cristina
dc.contributor.authorPons Espinal, Meritxell
dc.contributor.authorColini Baldeschi, Arianna
dc.contributor.authorCampa, Leticia
dc.contributor.authorArtigas Pérez, Francesc
dc.contributor.authorBortolozzi, Analia
dc.contributor.authorDomingo Jiménez, Rosario
dc.contributor.authorIbáñez, Salvador
dc.contributor.authorPineda, Mercè
dc.contributor.authorArtuch Iriberri, Rafael
dc.contributor.authorRaya Chamorro, Ángel
dc.contributor.authorGarcía Cazorla, Àngels
dc.contributor.authorConsiglio, Antonella
dc.date.accessioned2023-05-23T09:59:43Z
dc.date.available2023-05-23T09:59:43Z
dc.date.issued2023-02-06
dc.date.updated2023-04-14T11:15:49Z
dc.description.abstractTyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control-DAn from healthy individuals and gene-corrected isogenic controls. Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC. Treatment of THD-iPSC-DAn with L-Dopa rescued the neuronal defects and disease phenotype only in THDA-DAn. Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1757-4684
dc.identifier.pmid36740977
dc.identifier.urihttps://hdl.handle.net/2445/198344
dc.language.isoeng
dc.publisherEMBO
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.15252/emmm.202215847
dc.relation.ispartofEMBO Molecular Medicine, 2023, vol. 15, num. 3, p. e15847
dc.relation.urihttps://doi.org/10.15252/emmm.202215847
dc.rightscc by (c) Tristá Noguero, Alba et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationMalalties rares
dc.subject.classificationCèl·lules mare
dc.subject.classificationFenotip
dc.subject.classificationDopamina
dc.subject.otherRare diseases
dc.subject.otherStem cells
dc.subject.otherPhenotype
dc.subject.otherDopamine
dc.titleIPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
EMBO Mol Med - 2023 - Trist n‐Noguero - iPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal.pdf
Mida:
17.74 MB
Format:
Adobe Portable Document Format